GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants David Dodd – Chairman and Chief Executive Officer Mark Reynolds – Chief Financial Officer Mark Newman – Chief Scientific Officer John Sharkey – Head, Business Development Conference Call Participants Jason McCarthy - Maxim Group Jeff Kraws - Crystal Research Kumarguru Raja - Brookline Capital Markets Operator Good afternoon and welcome everyone to the GeoVax Second Quarter 2022 Corporate Update Ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) Delaware 8 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) Delaware 87-0455038 (State or other jurisdiction (IRS Employer Identification No.) 1900 Lake Pa ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2021 Earnings Conference Call March 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE, Investor Relations David Dodd - Chairman and Chief Executive Officer Mark Reynolds - Chief Financial Officer Mark Newman - Chief Scientific Officer John Sharkey - Head, Business Development Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Year End 2021 Corporate Update Call. I am Chuck with Cho ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of 87-0455038 (IRS Employer Identification Number) 1900 Lake Park ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2021 Earnings Conference Call November 11, 2021 4:30 PM ET Company Participants Jules Abraham - Investor Relations David Dodd - Chairman and Chief Executive Officer Mark Newman - Chief Scientific Officer Mark Reynolds - Chief Financial Officer John Sharkey - Head, Business Development Don Diamond - Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon and we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 1900 Lake Park Drive, Suite 380 Smyrna, Georgia 30080 (Address of principal executive of ices) (Zip Code (State or other jurisdiction (IRS Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2021 Earnings Conference Call August 11, 2021 4:30 PM ET Company Participants Jules Abraham - CORE, Investor Relations David Dodd - Chairman and Chief Executive Officer Mark Newman - Chief Scientific Officer Mark Reynolds - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group Jeffrey Kraws - Crystal Research Operator Good day and welcome to the GeoVax Second Quarter 2021 Corporate Update Call. I am [Gran], with Chorus Call and will facilitate ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) Delaware 87-0455038 (State or other jurisdiction (IRS Employer Id ...

Financial Data and Key Metrics Changes - Cash balances increased to $20.8 million as of March 31, 2021, compared to $9.9 million at December 31, 2020, primarily due to a February overnight offering that raised net proceeds of $9.4 million [35] - Working capital rose to $20.5 million from $9.4 million at the end of 2020 [35] - Net loss for Q1 2021 was $1.6 million or $0.29 per share, compared to a net loss of $596,000 or $2.54 per share in Q1 2020 [39] Business Line Data and Key Metrics Changes - Grant and collaboration revenues decreased to $110,000 in Q1 2021 from $716,000 in Q1 2020, primarily due to a shift in activities to external subcontractors for manufacturing work [37] - R&D expenses were $603,000 in Q1 2021, down from $809,000 in Q1 2020, reflecting the timing of grant expenditures [38] - General administrative expenses increased to over $1 million in Q1 2021 from $502,000 in Q1 2020, largely due to an increase in Delaware franchise tax and other administrative costs [38] Market Data and Key Metrics Changes - The company is focused on developing a universal coronavirus vaccine to provide broad and durable protection against emerging variants of SARS-CoV-2 [10][11] - The company is also advancing initiatives in immuno-oncology, with encouraging results from animal testing [16] Company Strategy and Development Direction - The company aims to provide a single-dose, safe, and durable universal coronavirus vaccine, leveraging technology that requires minimal refrigeration [10] - The focus remains on advancing the COVID-19 vaccine program and immuno-oncology developments while progressing other vaccine programs with minimal resource distraction [17] - The company is strengthening its intellectual property portfolio, with over 70 granted or pending patent applications [15] Management's Comments on Operating Environment and Future Outlook - Management highlighted the ongoing threat of emerging SARS-CoV-2 variants and the need for vaccines that can adapt to these changes [7][8] - The company anticipates further strengthening its balance sheet and is well-capitalized to advance priority programs into clinical development over the next 12 to 15 months [14] - Management expressed confidence in the potential for government funding to support clinical development of vaccines for hemorrhagic fevers, given the high fatality rates associated with these viruses [55][56] Other Important Information - The company has successfully raised over $10 million and added over $3 million from warrant exercises, resulting in a cash position of over $20 million [13] - The company is in discussions with federal government authorities regarding stockpile programs for vaccines targeting hemorrhagic fevers [56] Q&A Session Summary Question: Can you discuss the differences between mRNA vaccines and MVA-based vaccines regarding T-Cell immunity? - Management explained that MVA vaccines are designed to induce broader T-Cell memory responses, potentially providing long-term immunity with a single dose, unlike mRNA vaccines that may require multiple doses to address variants [48][50] Question: What is the status of the hemorrhagic fever virus programs? - Management acknowledged the government's interest in stockpiling vaccines for hemorrhagic fevers and indicated ongoing discussions regarding funding for clinical development based on positive animal testing results [55][56] Question: What are the company's thoughts on the Biden administration's discussions about waiving patent protections for COVID vaccines? - Management expressed concerns that waiving patent protections could inhibit innovation and emphasized the importance of allowing markets to operate effectively [59] Question: When is the MUC1 antigen program expected to move into the clinic? - Management indicated that the start of the trial will depend on the manufacturing schedule, with expectations to begin around mid to late next year [62] Question: How does the company plan to address the manufacturing challenges associated with MVA? - Management is actively evaluating continuous cell lines for MVA production and is in the process of selecting a contract development manufacturing operation to ensure scalability for future vaccine needs [88][89]